Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T21:28:40.574Z.
Calculation as of: 2026-10-06T21:28:40.574Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 673a23962afa1f964289f2c5c8e96f6ae4ccf5481b64718d91ae2e5553a82c87
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Market Cap
$174.27M
EV/EBIT Ratio
N/A
TTM Avg
0.27x
3Y Avg
0.27x
5Y Avg
0.27x
Market Cap
$172.42M
EV/EBIT Ratio
N/A
TTM Avg
286.64x
3Y Avg
136.18x
5Y Avg
72.17x
Market Cap
$171.13M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$169.53M
EV/EBIT Ratio
N/A
TTM Avg
50.33x
3Y Avg
50.33x
5Y Avg
50.33x
Market Cap
$179.26M
EV/EBIT Ratio
N/A
TTM Avg
25.06x
3Y Avg
25.06x
5Y Avg
25.06x
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| ProQR Therapeutics N.V. (PRQR) | $173.76M | N/A | N/A | N/A | N/A |
| Yarrow Bioscience Inc (YARW)vs › | $174.27M | N/A | 0.27x | 0.27x | 0.27x |
| Organogenesis Holdings Inc. (ORGO)vs › | $172.42M | N/A | 286.64x | 136.18x | 72.17x |
| Precision BioSciences, Inc. (DTIL)vs › | $171.13M | N/A | N/A | N/A | N/A |
| Journey Medical Corporation (DERM)vs › | $169.53M | N/A | 50.33x | 50.33x | 50.33x |
| MediWound Ltd. (MDWD)vs › | $168.92M | N/A | 8.18x | 8.18x | 8.18x |
| Oramed Pharmaceuticals Inc. (ORMP)vs › | $179.26M | N/A | 25.06x | 25.06x | 25.06x |
| Cue Biopharma, Inc. (CUE)vs › | $168.10M | N/A | N/A | N/A | N/A |
| Compass Therapeutics, Inc. (CMPX)vs › | $179.75M | N/A | N/A | N/A | N/A |
| Canton Strategic Holdings Inc (CNTN)vs › | $180.47M | N/A | N/A | N/A | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
